Non-Relapse Mortality With Bispecific Antibodies in Hematologic Malignancies: A Dual Systematic Review and Pharmacovigilance Analysis.
Infection control during bispecific antibody treatment emerges as crucial to reducing deaths unrelated to disease progression.
This systematic review and meta-analysis examined Non-Relapse Mortality With Bispecific Antibodies in Hematologic Malignancies: A Dual Systematic Review and Pharmacovigilance Analysis. The PubMed abstract reports that Given the risks associated with prolonged treatment, future protocols must prioritize infection management and adopt NRM as a standardized endpoint to guide appropriate therapeutic selection and sequencing.
What the study was
- Study design
- Systematic review and meta-analysis
- Population
- patients with relapsed/refractory (R/R) hematological malignancies (HMs)
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Hematological oncology
Why it surfaced
Score 5/10 reflects systematic review and meta-analysis evidence with abstract only access; genuine match to Hematologic malignancies, Novel therapeutics: immunotherapy, CAR-T, targeted therapy, Aging, longevity, and population health.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.